Louise Chen
Stock Analyst at Scotiabank
(2.24)
# 2,539
Out of 4,829 analysts
299
Total ratings
40.21%
Success rate
-4.83%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.26 | +614.29% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $14.58 | -3.98% | 2 | Apr 3, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sector Perform | $105 → $80 | $36.27 | +120.57% | 2 | Mar 20, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.93 | +521.76% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $18.56 | +196.42% | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Initiates: Sector Outperform | $150 | $97.17 | +54.37% | 1 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $44.23 | +24.35% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $2.35 | +538.30% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $22.77 | +119.59% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $3.62 | +314.36% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $4.81 | +253.43% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $27.87 | +151.17% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $11.41 | +338.21% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $13.44 | +123.21% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $29.24 | +88.10% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.62 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $65.77 | +143.27% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.16 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $22.28 | +101.97% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $154.22 | +39.41% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.87 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $75.97 | +104.03% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.64 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $734.57 | +20.48% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.80 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.02 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.97 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.10 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.63 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $184.60 | +8.34% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.82 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.89 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.38 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.20 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $527.78 | +75.26% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.94 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $6.99 | +829.90% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.81 | +517.44% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $0.88 | +2,740.91% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.21 | +251.86% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.53 | +269.55% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.46 | +242.47% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $1.30 | +592.31% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $8.51 | +19,829,512.22% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $454.62 | -43.25% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $16.93 | -11.40% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $2.11 | +2,269.67% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.24 | +1,512.90% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.88 | +554.07% | 1 | Jun 22, 2017 |
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.26
Upside: +614.29%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $14.58
Upside: -3.98%
Sarepta Therapeutics
Mar 20, 2025
Maintains: Sector Perform
Price Target: $105 → $80
Current: $36.27
Upside: +120.57%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.93
Upside: +521.76%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.56
Upside: +196.42%
Blueprint Medicines
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $150
Current: $97.17
Upside: +54.37%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $44.23
Upside: +24.35%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.35
Upside: +538.30%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $22.77
Upside: +119.59%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.62
Upside: +314.36%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $4.81
Upside: +253.43%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $27.87
Upside: +151.17%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $11.41
Upside: +338.21%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $13.44
Upside: +123.21%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $29.24
Upside: +88.10%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.62
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $65.77
Upside: +143.27%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.16
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $22.28
Upside: +101.97%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $154.22
Upside: +39.41%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.87
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $75.97
Upside: +104.03%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.64
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $734.57
Upside: +20.48%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.80
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.02
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.97
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.10
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.63
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $184.60
Upside: +8.34%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.82
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.89
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.38
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.20
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $527.78
Upside: +75.26%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.94
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $6.99
Upside: +829.90%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $0.81
Upside: +517.44%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $0.88
Upside: +2,740.91%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.21
Upside: +251.86%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.53
Upside: +269.55%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.46
Upside: +242.47%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $1.30
Upside: +592.31%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $8.51
Upside: +19,829,512.22%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $454.62
Upside: -43.25%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $16.93
Upside: -11.40%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $2.11
Upside: +2,269.67%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.24
Upside: +1,512.90%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $6.88
Upside: +554.07%